David Fajgenbaum

Every Cure Co-Founder Receives the Inaugural Elevate Prize Founder's Award for their Bold Mission of Saving Lives with Existing Drugs

Retrieved on: 
Wednesday, November 1, 2023
FDA, Intelligence, David Fajgenbaum, Life, Hope, Organization, Entrepreneurship, Disease, Medicine, Pharmacy, Algorithm, Patient, PR, Pharmaceutical industry, Medical device

PHILADELPHIA, Nov. 1, 2023 /PRNewswire/ -- The Elevate Prize Foundation officially announced today that Every Cure Co-Founder, Dr. David Fajgenbaum, is the inaugural recipient of the Elevate Prize Founder's Award in recognition of Every Cure's bold mission to find new uses for existing drugs. Every Cure is a nonprofit organization committed to ensuring that no patient suffers when their potential cure sits within reach on the pharmacy shelf.

Key Points: 
  • PHILADELPHIA, Nov. 1, 2023 /PRNewswire/ -- The Elevate Prize Foundation officially announced today that Every Cure Co-Founder, Dr. David Fajgenbaum, is the inaugural recipient of the Elevate Prize Founder's Award in recognition of Every Cure's bold mission to find new uses for existing drugs.
  • Every Cure is a nonprofit organization committed to ensuring that no patient suffers when their potential cure sits within reach on the pharmacy shelf.
  • The Elevate Prize Founder's Award includes an unrestricted grant for leaders and their organizations to advance their impact.
  • Maybe they don't fit the criteria for one of our other prizes, so the Elevate Prize Founder's Award is poised to fill that gap.

Every Cure Announces Foundational Funding Partners and Major Milestones at Clinton Global Initiative 2023 Meeting

Retrieved on: 
Monday, September 18, 2023
Pennsylvania State University, White House, Partnership, Pharmacy, Drug development, Intelligence, MBA, History, Science In Society, Government, White, Organization, Chan Zuckerberg Initiative, Discovery, Flagship Pioneering, MD, Patient, Master of Science, David Fajgenbaum, Artificial intelligence, Biology, Lewis Hall (politician), CGI, Rare, FDA, CZI, Disease, Pfizer, Data science, Pharmaceutical industry, Medical device, Management, Science

PHILADELPHIA, Sept. 18, 2023 /PRNewswire/ -- Every Cure, a non-profit organization committed to unlocking additional diseases and patients that can benefit from existing drugs, announced today at the Clinton Global Initiative (CGI) 2023 Meeting, four foundational funding partners. These partnerships with Chan Zuckerberg Initiative, Flagship Pioneering, Lyda Hill Philanthropies, and Elevate Prize Foundation will be used to discover new previously und­­­iscovered uses for existing approved drugs by leveraging novel artificial intelligence (AI) tools.

Key Points: 
  • "Together, with our foundational funding partners, we will drive innovation and accelerate the discovery of new treatment options for devastating medical conditions, ultimately transforming the lives of countless individuals."
  • Chan Zuckerberg Initiative (CZI), a leading tech and philanthropic organization, is partnering by contributing funding and data science support.
  • In addition to making major discoveries that save lives, Every Cure will need to continue to raise awareness and disseminate findings among stakeholders.
  • For further information or to express interest in partnering with Every Cure, please contact Brent Shaw ( [email protected] , 818-876-2691).

Angiosarcoma Patient Celebrates 7-Year Remission with Pioneering Use of PD-1 Inhibitor: Every Cure Unleashes AI to Ensure No Treatment is Left Overlooked

Retrieved on: 
Wednesday, August 2, 2023
University, Cancer, PET, Prognosis, National Comprehensive Cancer Network, Organization, Patient, Standard of care, Algorithm, David Fajgenbaum, Artificial intelligence, Diagnosis, PD-1, FDA, Pembrolizumab, Health, PD-L1, Disease, Pharmaceutical industry, Medical device, Angiosarcoma

PHILADELPHIA, Aug. 2, 2023 /PRNewswire/ -- A patient cured of angiosarcoma from a pioneering use of a repurposed PD-1 inhibitor is celebrating seven years of remission after the treatment was hidden in the medical literature before being discovered by Every Cure Co-founder Dr. David Fajgenbaum and his team at the University of Pennsylvania. Every Cure and its partners are developing medical databases and AI algorithms to ensure no potential cure remains overlooked among the vast number of medical studies.

Key Points: 
  • Every Cure and its partners are building on this breakthrough, deploying innovative AI algorithms that evaluate the potential of every drug for every disease.
  • Every Cure and its partners are developing medical databases and AI algorithms to ensure no potential cure remains overlooked among the vast number of medical studies.
  • In 2016, Michael was confronted with a diagnosis of metastatic angiosarcoma and given a prognosis of just three months.
  • Every Cure is committed to ensuring no potential cure remains overlooked in the vast number of medical studies performed each year.

WW International, Inc. Announces Upcoming Changes to Board of Directors

Retrieved on: 
Thursday, March 23, 2023
Interim, Music, WW International, Penn State Board of Trustees, True North Venture Partners, Senior advisor, Computer science and engineering, Electrical engineering, Dartmouth College, Electricity, WW, Acquisition, David Fajgenbaum, Annual general meeting, Computer science, Insight Partners, Massachusetts Institute of Technology, Management, INVU (song)

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced several upcoming changes to its Board of Directors (the “Board”) in connection with the Company’s annual meeting of shareholders to be held on May 9, 2023 (the “2023 Annual Meeting”).

Key Points: 
  • NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced several upcoming changes to its Board of Directors (the “Board”) in connection with the Company’s annual meeting of shareholders to be held on May 9, 2023 (the “2023 Annual Meeting”).
  • Directors Raymond Debbane, who currently serves as Chairman of the Board, and Jonas Fajgenbaum will not be standing for re-election at the 2023 Annual Meeting.
  • Mr. Debbane will step down as Chairman effective as of the midnight prior to the 2023 Annual Meeting.
  • The Board has appointed Thilo Semmelbauer as Chairman of the Board effective May 9, 2023, the day of the 2023 Annual Meeting.